newsfilter
← Latest News
GlobeNewswire·

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

ICU
  • SeaStar Medical added three top-rated children's hospitals to its QUELIMMUNE customer base, increasing second quarter 2026 net revenue by 82% to $0.6 million compared to $0.3 million in the same period of 2025.
  • Enrollment in the NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients reached 223 of 339 patients, with completion anticipated by year-end 2026 or early 2027 to enable a PMA application near the end of 2027.
  • The company obtained ICD-10-PCS codes from CMS for its Selective Cytopheretic Device therapy, allowing standardized inpatient billing effective October 1, 2026.
  • Research and development expenses rose to $2.5 million in the second quarter of 2026 from $1.0 million in 2025, driven by increased clinical trial costs & personnel expenses.
  • General and administrative expenses increased to $1.8 million in the second quarter of 2026 from $1.0 million in 2025 due to higher compensation, legal fees, & SEC-related costs.
  • The company reported a net loss of $3.7 million ($0.91 per share) for the three months ended June 30, 2026, compared to a net loss of $2.0 million ($1.77 per share) in the prior year period.
  • Cash balances decreased to $7.0 million at June 30, 2026, from $12.0 million at December 31, 2025, while gross margins for QUELIMMUNE sales remained high at 91%.
  • SeaStar Medical sponsored the KidneyBee Summit 2026 & hosted an educational webinar on pediatric sepsis-associated AKI featuring leading experts in the field.
  • The company holds Breakthrough Device Designation from the FDA for six therapeutic indications, supporting potential accelerated pathways for its SCD therapy.